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Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors occurring mainly in
patients with chronic liver disease. Detection of early HCC is critically important for treatment of these patients.
Methods: We employed a proteomic profiling approach to identify potential biomarker for early HCC detection.
Based on Barcelona Clinic Liver Cancer (BCLC) staging classification, 15 early HCC and 25 late HCC tissue samples
from post-operative HCC patients and their clinicopathological data were used for the discovery of biomarkers
specific for the detection of early HCC. Differential proteins among cirrhotic, early, and late tissue samples were
separated by two-dimensional gel electrophoresis (2-DE) and subsequently identified by mass spectrometry (MS).
Receiver operating characteristic (ROC) curves analysis were performed to find potential biomarkers associated with
early HCC. Diagnosis performance of the biomarker was obtained from diagnosis test.
Results: Protein spot SSP2215 was found to be significantly overexpressed in HCC, particularly in early HCC, and
identified as heterogeneous nuclear ribonucleoprotein K (hnRNP K) by tandem mass spectrometry (MALDI TOF/TOF).
The overexpression in HCC was subsequently validated by western blot and immunohistochemistry. ROC curve
analysis showed that hnRNP K intensity could detect early HCC at 66.67 % sensitivity and 84 % specificity, which was
superior to serum α-fetoprotein (AFP) in detection of early HCC. Furthermore, the diagnosis test demonstrated, when
combined with hnRNP K and serum AFP as biomarker panel to detect early HCC at different cut-off value, the
sensitivity and specificity could be enhanced to 93.33 % and 96 %, respectively.
Conclusions: hnRNP K is a potential tissue biomarker, either alone or in combination with serum AFP, for detection
of early HCC. High expression of hnRNP K could be helpful to discriminate early HCC from a nonmalignant nodule,
especially for patients with liver cirrhosis.
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Hepatocellular carcinoma is one of the most common
malignant tumors worldwide and is particularly preva-
lent in China and Asia. Persisting viral infections such as
Hepatitis B (HBV) and Hepatitis C (HCV), which are
the major common risk factors of HCC, is responsible
for about 80% of all HCC [1]. Chronic infection with* Correspondence: guoyantong2008@yahoo.com.cn
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reproduction in any medium, provided the orHBV in the setting of cirrhosis increases the risk of
HCC 70-fold [2]. In China, most HCC cases develop in
patients with advanced chronic liver disease caused by
HBV infection once cirrhosis has developed, retrospect-
ive studies have suggested that patients will develop ei-
ther hepatic decompensation or HCC at a rate of 2% to
7% per year [3].
For diagnosis of early HCC, patients with liver cirrho-
sis are advised to undergo periodic screening of serum
AFP concentration and liver ultrasound at 6-to 12-
monthintervals [4]. However, even with this screening. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological features of 15 early and 25
late HBV-related HCC
Feature Early HCC (n= 15) Late HCC (n = 25)
Sex
Male 13 (87 %) 21 (84 %)
Female 2 (13 %) 4 (16 %)
AgeA 53.67 ± 10.80 53.40 ± 12.59
AFP(ng/mL)A 629.07 ± 561.23 56682.04 ± 6704.74
Tumor size(cm)A,B 2.33 ± 0.48 10.84 ± 3.04
Venous invasion
Absent 15 (100 %) 18 (72 %)
Present 0 (0) 7 (28 %)
Microsatlite lesion
Absent 15 (100 %) 16 (64 %)
Present 0 (0) 9 (36 %)
Liver function
Grade A 15 (100 %) 14 (56 %)
Grade B 0 (0) 11 (44 %)
Grade C 0 (0) 0 (0)
Tumor stage (AJCC)
Stage I 15 (100 %) 0 (0)
Stage II 0 (0) 12 (48 %)
Stage IIIA&B 0 (0) 13 (52 %)
A Mean ± SD.
B Measured by the length of the largest tumor nodule.
cChild-pugh classification.
AFP, Alpha Fetoprotein; AJCC, AJCC, The American Joint Committee on Cancer.
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HCC (>5 cm), multifocal tumor (more than 3 lesions),
or HCC that has invaded the biliary duct or portal vein.
The major limitations of ultrasound is its poor ability to
differentiate malignant from benign nodules in a cir-
rhotic liver. Serum AFP, the most commonly used bio-
marker of HCC, has a reported sensitivity of 39% to 65%
and specificity of 65% to 94%, depend on different cut-
off values. It is suggested AFP can be used to define
patients at risk for HCC, but has limited utility as a
screening test [5]. AFP has multiple limitations when ap-
plied to the detection of small tumors [6–8], and varies
significantly in the presence of benign nodules or non-
malignant liver disease [9,10]. Therefore, there is still a
need to search for biomarkers that are specifically asso-
ciated with early HCC, especially in the presence of
cirrhosis. Studies to extend our knowledge about the
molecular pathogenesis of HCC, to identify HCC bio-
markers, and therefore enable early diagnosis of HCC
would be of great clinical benefit.
The proteome of tumor tissue is a rich source of can-
cer biomarkers, and protein released from tumor tissues
may be more cancer specific than those from non-
tumor tissue. Investigation of the tumor tissue prote-
ome can identify proteomic signatures corresponding to
clinicopathological features, and individual protein in
such signatures may be good biomarker candidate [11].
In spite of many recent technological advances in meth-
ods for the separation and analysis of protein, two-
dimensional gel electrophoresis (2-DE) coupled with
tandem mass spectrometry MS is still the “gold stand-
ard” technique [12].
In the present study, proteomic 2-DE approach was
used to analyze HCC patients. hnRNP K was successfully
identified as a candidate biomarker for early HCC, when
compared to cirrhosis controls. The sensitivity and spe-
cificity of hnRNP K alone or in combination with AFP
in relevant clinical populations make this a suitable tool
for the detection of early HCC.
Materials and methods
Patient selection
All patients included in this study suffered from cirrho-
sis with chronic HBV infection (Table 1). BCLC staging
classification is best for treatment guidance and selection
of early-stage patients that could benefit from curative
therapies [13]. In this classification, early HCC is defined
as a single node of HCC measuring< 3 cm, or up to 3
nodes< 3 cm each, Child-Pugh A-B class, with no symp-
toms and lack of change in performance status [14]. In
this study, patients were divided into either early HCC
group or late HCC group according to the BCLC staging
system. Paired tissues were obtained from each patient,
one from the cirrhotic region adjacent to the tumor andthe other from the tumor region of the resected liver.
The 15 recruited patients with early HCC tumors had a
Child Pugh liver function score of grade A, The 25 late
HCC patients were recruited with no particular selection
criteria. The 40 paired cirrhotic liver tissues were diag-
nosed histologically, with activity ranging from mild to
severe. All resected tissues were collected between 1998
and 2006 at Beijing Jishuitan Hospital. Separate tissue
samples from a cohort of HCC patients (n = 20) from
the same hospital were used to validate the biomarker
performance. This study was approved by the ethics
committee, and all the tissues were collected with
informed consent from patients.
Sample preparation and 2-dimensional gel
electrophoresis
Tissues were immediately snap-frozen in liquid nitrogen
after surgical resection and stored at −80°C prior to ana-
lysis. Proteins were extracted from around 10 mg tis-
sue with Bio-Rad (Hercules, CA, USA) ReadyPrepTM
Sequential Extraction Kit. Tissues were first homoge-
nized in 0.1 ml 40 mM Tris base supplemented with
20 μg/ml RNase A (bovine pancreas source, USB,
AC
B
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Figure 1 Overexpression of hnRNP K in HCC tissues. (A)
Representative protein profile of tissue sample from a late HCC
patient is shown. The black rectangle entails the protein spot
SSP2215. (B) Different expression of hnRNP K among cirrhosis
(n = 40), early HCC(n = 15), and late HCC(n = 25) tissues in 2-DE gel.
The protein spot marked with a square on two-dimensional gel
electrophoresis image is protein SSP2215. (C) Histograms with
relative protein intensities shows protein spot SSP2215
overexpressed in early and late HCC tissues compared with cirrhosis
tissue. ?, p< 0.01; ??, p< 0.01.
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source, USB) and complete EDTA-free protease inhibitors
(Roche, Mannheim, Germany) with a mini-pestle fitted in
Pellet Pestle Motor (Kontes Bineland, NJ, USA). After
centrifugation at 20,800 g, pellets were homogenized in
0.1 ml extraction solution containing 8 M urea, 4%(w/v)
CHAPS, 40 mM Tris, 0.2%(w/v) carrier ampholytes and
2 mM tributyl phosphine. After centrifugation at 20,800 g
for 60 minutes at 15°C, protein concentrations in the
supernatants were quantitated with PlusOne 2-DE
Quant Kit (Amersham Biosciences, Piscataway, NJ,
USA). The first-dimensional IEF was performed using
precast 18 cm IPG strips at 20°C with a maximum
current setting of 50 μA/strip using an Amersham-
Biosciences IPGphor IEF unit. IEF was carried out
using the following conditions: i) 200 V, 200Vh; ii)
500 V, 500Vh; iii) 1000 V, 500Vh; iv) 1000 V-8000 V;
2250Vh; and v) 8000 V; 32000Vh. The strips were
loaded onto the second dimension after equilibration.
After the strips had been transferred onto 12.5% pre-
cast EttanTM DALTElectrophoresis Unit (Amersham
Biosciences). Gels were then stained with a protein
silver stain kit (Amersham Biosciences) following the
manufacturer’s protocol.
Gel imaging and analysis
Gel images were captured with GS-800 Calibrated
Densitometer (Bio-Rad, Hercules, CA, USA). Digital
images were analyzed with PDQuest 7.2 (Bio-Rad,
Hercules, CA, USA). The analysis included spot detec-
tion, matching, and normalization. The intensity of each
spot was normalized by total valid spot volume, and was
reported as relative value (in ppm). One-way ANOVA
(analysis of variance) test was used to analyze spot inten-
sities in cirrhosis, early and late HCC samples. Only sta-
tistically significant (p< 0.01) spots were chosen for
further mass spectrometric analysis.
In-gel trypsin digestion and mass spectrometry
Protein spots were excised manually with syringe nee-
dles. Gel plugs were firstly destained with 15 mM po-
tassium ferricyanide/50 mM sodium thiosulfate for 20
minutes and washed with Milli-Q water. The gel
pieces were then equilibrated in 50 mM ammonium
bicarbonate/50% methanol. After drying in SpeedVac
concentrator (Savant, Farmingdale, NY, USA) for 15min-
utes, trypsin (MS grade, Promega, Madison, WI, USA)
was added at a final concentration of 20 ng/ul to fully
cover the gel pieces. Digestion was performed at 37°C
overnight. Peptides were recovered with 35ul 0.1% TFA/
50% acetonitrile twice. All supernatants were pooled and
dried in SpeedVac concentrator for 1 hour. Prior to con-
centration purification with ZopTipW pipette tips
(Millipore, Bedford, MA, USA), peptides were dissolved
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with 1 ul of 50% acetonitrile/0.1% TFA, which then
mixed with same volume of matrix (10 mg/ml α-
cyano-4-hydroxycinnamic acid in 50% acetonitrile 0.1%
TFA). Finally, the mixtures were spotted onto the sam-
ple plate and allowed to air-dry. MS/MS spectra data
were generated by ABI 4800 Proteomics Analyzer
MALDI TOF/TOF (Applied Biosystems, CA, USA). A
maximum of 5 most intense tandem mass spectra were
collected for MS/MS in positive ion mode and of collision
energy 2 kV. Mono-isotopic peaks were automatically
determined and fragment ion masses were compared with
the NCBI database for protein identification using the
MASCOT version 2.1 (Matrix Science).Western blot
Twenty-five micrograms of protein extract was loaded
for SDS-PAGE. After electroblotting, membrane was
washed with TBS-T (20 mM Tris, 137 mM NaCl, 0.1%
Tween-20, pH 7.6). The membrane was incubated in
blocking solution: TBS-T/5% (w/v) non-fat dry milk/1%
(w/v) BSA with gentle shaking at room temperature for
1 hour. Incubation with mouse monoclonal anti-hnRNP
K antibody (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) at 1:1500 dilution was performed at 4°C over-
night. The next day, the membrane was washed with
TBS-T(3 × 10 minutes), and incubated with horserad-
ish peroxidase conjugated goat anti-mouse antibody
at 1:1000 dilution for 1 hour at room temperature.
After thoroughly washing with TBS-T(3 × 10 minutes),Table 2 Summary of protein spot SSP2215 identified by tand
Spot. No. 2215:HNRPK_Human, P61978
(Heterogeneous nuclear ribonucleoprotein K hnRNP K transformation u
Submitted mass Intensity Experimental mass mW Delta
873.4976 19253.86 872.4898 872.4967 7.9049
997.4429 16550.303 996.4351 996.4335 −1.592
998.3858 11027.003 997.378 997.3812 3.2434
1013.4338 1971.4678 1012.426 1012.428 2.3512
1053.6353 10501.342 1052.6274 1052.634 6.3782
1106.5122 32201.934 1105.5044 1105.507 2.7605
1122.5112 3962.2905 1121.5034 1121.502 −1.088
1194.6987 61029.887 1193.6909 1193.692 0.8181
1259.5726 31493.924 1258.5648 1258.568 2.3278
1340.8009 16949.094 1339.7931 1339.796 2.46
1518.9299 20096.148 1517.9221 1517.929 4.8252
1579.7023 7277.207 1578.6945 1578.699 2.5517
1735.8025 8286.643 1734.7947 1734.8 2.8146
1780.8018 25691.514 1779.7939 1779.791 −1.577
1917.0393 14311.455 1916.0315 1916.026 −3.058immunoreactive proteins were visualized with ECL
detection reagents (Amersham Biosciences) and X-ray
film (Fuji Photo Film, Tokyo, Japan). β-Actin was included
as protein loading control using goat anti-human actin
antibody (Santa Cruz Biotechnology, Inc.) at 1:1000 dilu-
tion for normalization.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-
embedded HCC tissues at 6 μm sections that were
quenched with peroxide and blocked with 3% normal
goat serum and 1% BSA. Primary antibody specific for
mouse anti-hnRNP K antibody (sc-28380, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) was added to
the sections and incubated at 4°C overnight, followed by
the horseradish peroxidase-conjugated goat anti-mouse
second antibody for 30 minutes at room temperature.
The sections were observed with an Olympus light
microscope using 10 × and 40× objectives.
Statistical analysis
SPSS for Windows (version 12.0, SPSS, Chicago, IL,
USA) and Graphpad Prism 5.01 was used to perform
statistical analysis. One-way ANOVA, Student’s t-test
were adopted in this study whenever applicable. The
correlation between candidate biomarker and clinico-
pathological data was performed by nonparametric cor-
relation analysis. Receiver operating characteristic (ROC)
curves were performed to determine the area under the
curve (AUC), and a cut-off value was selected forem mass spectrometry
p regulated nuclear protein TUNP)
(ppm) Start End Sequence Modifications
397 405 (K)DLAGSIIGK(G) -
6 317 325 (R)GGDLMAYDR(R) -
279 286 (R)DYDDMSPR(R) -
317 325 (R)GGDLMAYDR(R) Oxidation M (5)
192 201 (R)VVLIGGKPDR(V) -
38 46 (R)NTDEMVELR(I) -
5 38 46 (R)NTDEMVELR(I) Oxidation M (5)
306 316 (R)NLPLPPPPPPR(G) -
423 433 (K)IDEPLEGSEDR(I) -
208 219 (K)IILDLISESPIK(G) -
149 163 (R)LLIHQSLAGGIIGVK(G) -
22 34 (K)RPAEDMEEEQAFK(R) -
22 35 (K)RPAEDMEEEQAFKR(S) -
5 70 86 (R)TDYNASVSVPDSSGPER(I) -
1 378 396 (R)GSYGDLGGPIITTQVTIPK(D) -
AB
C Early HCC Late HCC
Tumor 
Peri-tumor 
Figure 2 Validation of hnRNP K overexpressed in HCC of different tumor stages. (A) Representative Western blot analysis demonstrates
hnRNP K overexpressed in different stages of HCC tumors compared to cirrhosis samples. β-actin was used as internal loading control. The ratio
of hnRNP K/β-actin protein was measured using Scion Image Beta 4.03 software. (B) Histograms showed the average densitometric ratio of
hnRNP K to β-actin in early and late HCC tissue compared with cirrhosis control (?, p< 0.05). (Early HCC/cirrhosis = 3.48; Late HCC/cirrhosis = 3.30).
(C) Representative Immunohistochemical staining showed the expression level and cellular localization of hnRNP K in early, late HCC tissues, and
peri-tumor cirrhosis tissues. Stronger signal was found at the nucleus than that in cytoplasma in tumor cells, but limited nucleus staining in
cirrhotic tissues (Original magnification× 400).
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Table 3 The correlation between hnRNP K intensity and
clinicopathological variables in HCC
1
Variables Coefficient p value
Serum AFP −0.088 0.593A
tumor size 0.361 0.022A
Venous invasion 0.257 0.109B
Microsatellite 0.378 0.016B
Tumor stage(AJCC)C 0.322 0.059B
A p value were obtained by Pearson correlation analysis.
B p value were obtained by Spearman’s rank correlation analysis.
C AJCC, The American Joint Committee on Cancer.
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formance of hnRNP K, serum AFP, were also calculated
using tabular methods to evaluate the usefulness of these
biomarker as individual or combined tests for early HCC
according to the diagnosis test [15]. P values of less than
0.05 were considered statistically significant. Continuous
data were presented as the mean± SD.
Results
Overexpression of hnRNP K in early HCC tissue
Protein spots that showed at least two-fold changes and
a significant difference in intensity (p< 0.05) between
HCC and cirrhotic liver samples were included for fur-
ther analysis. Among the proteins identified as up-
regulated using mass spectrometry, the protein labeled
SSP2215 was found to be consistently overexpressed
in HCC tissues compared with cirrhotic liver tissues
(p< 0.01) (Figure 1A). This protein was expressed
more strongly than other candidate biomarkers in all
HCC tumors of different stages (p< 0.01) (Figure 1B).
Because detection of early HCC in high risk subjects
(e.g., those with cirrhosis and/or hepatitis B) could
guide further treatment and improve patients’ clinical
outcomes, we were motivated to distinguish any po-
tential biomarker with expression related to early
HCCs. Intriguingly, a stronger expression of SSP2215
was found to be significant in early HCCs compared
to other protein spots. Moreover, significant overex-
pression of this protein was maintained in late HCC
tumors, suggesting that expression of SSP2215 may be
related to HCC development (Figure 1C). Finally, the
SSP2215 spot was identified as heterogeneous nuclear
ribonucleoprotein K (hnRNP K) (homo sapiens, P61978)
by mass spectrometry (Table 2), and selected for further
validation in a separate cohort.
Database: MASCOT, NCBInr
Validation of hnRNP K overexpression in HCC tissues
To confirm the results from 2-DE analysis, additional
independent samples from 10 early HCCs, 10 late
HCCs and 20 corresponding adjacent non-tumor tis-
sues were examined to validate the hnRNP expression.
Overexpression of hnRNP K protein in the HCC tissue
was further confirmed by Western blot and immuno-
histochemistry staining. In accordance with the 2-DE
results, hnRNP K expression level was higher in both
the early HCC and late HCC group compared with the
cirrhosis group (Figure 2). The expression of hnRNP
K in the early and late HCC group was 3.5-fold and
3.3-fold higher stronger, respectively, when compared
to the cirrhosis tissue (Figure 2A and 2B). Likewise,
immunohistochemistry staining showed that a stronger
localized immunoreactivity signal of hnRNP K was
revealed in the nucleus when compared to the cytoplasmof HCC tumor cells, but limited nuclear immunoreactiv-
ity was found in cirrhotic tissues (Figure 2C).
Clinical significance of hnRNP K expression in HCC
Clinicopathological correlation with hnRNP K expression
was analyzed in a total of 40 human HBV-associated
HCCs. Overexpression of hnRNP K was shown to be
significantly correlated with the increased tumor size
(p = 0.022) and microsatelite nodules (p = 0.016), re-
spectively. There was no apparent correlation with
other clinicopathological features, including serum AFP
concentration and venous invasion (Table 3).
hnRNP K is a potential biomarker for early HCC
To assess the individual performance of hnRNP K as a
potential biomarker to discern early HCC from cirrhosis,
and to detect early HCC from late HCC in tissue, we
selected optimal fixed cutoff thresholds for hnRNP K
and then calculated test sensitivity and specificity by re-
ceiver operating characteristic (ROC) curves (Figure 3).
At a cutoff threshold of ≥6.396 ppm, hnRNP K showed a
high accuracy to discern early HCC tissue from cirrhosis
tissue with a sensitivity of 93.33% and a specificity of
75% (AUC= 0.89, p< 0.01) (Figure 3A). Likewise,
hnRNP K separated early HCC from late HCC at a
cutoff threshold of 7.16 ppm with a sensitivity of
66.67% and a specificity of 84% (AUC= 0.75, p< 0.01)
(Figure 3B). Serum AFP had a lower diagnostic cap-
ability (AUC= 0.60, p> 0.05) of detecting early HCC
from late HCC either at a cutoff value of 100 ng/mL
(Sen = 64.29%, Spe = 56%) or 400 ng/mL (Sen = 64.29%,
Spe = 40%) (Figure 3C), which is in accordance with
the acknowledged reports that AFP is insensitive for
early HCC detection.
It is well known that the combination of multiple bio-
markers will improves capability for disease diagnosis. In
order to further evaluate the diagnostic performance of
hnRNP K with serum AFP, we performed serial and par-
allel diagnosis tests (Table 4). The parallel test requires
that either hnRNP K or serum AFP are abnormal to
classify a patient as early HCC. We used fixed cutoff
B 
A                      
C
Figure 3 Diagnostic performance of hnRNP K and serum AFP in
detection of HCC. The diagnostic accuracy of hnRNP K and AFP,
in terms of sensitivity and specificity, are presented by receiver
operating characteristic (ROC) curve analysis. In figures 3B and 3 C,
corresponding to hnRNP K and AFP, the area under the curve for
hnRNP K is markedly better than for the AFP in detecting early
HCC. (A) ROC curve of hnRNP K in detection of HCC from
cirrhosis (AUC= 0.89, Sen = 93.33%, Spe= 75%). (B) ROC curve of
hnRNP K in detection of early HCC from late HCC (AUC= 0.75,
Sen = 66.67%, Spe = 84%). (C) ROC curve of serum AFP in
detection of early HCC from late HCC (AUC= 0.60). (Sen = 64.29%,
Spe= 56%, cut-off value≥ 100 ng/mL; Sen = 64.29, Spe= 40%,
cut-off value≥ 400 ng/mL). the two cut-off points of AFP are
indicated with arrow.
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to discern early HCC from late HCC with a sensitivity of
93.33%, specificity of 44% and accuracy of 62.5%. In con-
trast, the serial test, with fixed cutoff thresholds of
7.16 ppm hnRNP K and 100 ng/mL AFP, requires that
both hnRNP K and AFP are abnormal, and it increased
specificity and accuracy to 96% and 72.5%, respectively,
at the expense of sensitivity (33.33%) when early HCC
were compared to late HCC. If a higher threshold of
AFP (400 ng/mL) was combined with hnRNP K, the
overall accuracy decrease either in the parallel test
(62.5% vs 55%) or in the serial test (72.5% vs 70%), sug-
gested that the combination of fixed hnRNP K with rela-
tive lower AFP (100 ng/mL) as a cutoff threshold was
more powerful to diagnose early HCC.
Discussion
Development of HCC is a complex process involving
multiple changes in gene and protein expression. It usu-
ally occurs in the presence of liver cirrhosis. Detection
of early HCC in patients with chronic liver cirrhosis is
crucial, since the most effective treatments for early
HCC are curative. Patients diagnosed at an early HCC
stage are optimal candidates for resection, liver trans-
plantation, or percutaneous ablation with the possibility
of long term cure.
Our target was to identify disease-related proteins
present in the early HCC tumor tissues by tissue proteo-
mics, which would lead to a better understanding of the
mechanisms driving tumor development. Furthermore,
it has been demonstrated that protein expression profiles
of cancer obtained by 2-DE and mass spectrometry
could provide useful biomarkers for early detection and
prognostic prediction [16,17].
Therefore, we employed 2-DE-MS proteomic analysis
of 40 subjects to identify protein that enabled detection
of early HCC. hnRNP K was selected to be identified
and further validated both because of its high expression
level in HCC tissue compared to the cirrhosis control
(AUC=0.89, p< 0.01), and its capability of distinguishing
Table 4 Diagnosis performance of hnRNP K and serum AFP as biomarker panel for detection of early HCC
Test features Parallel test Serial test
hnRNP K ≥7.160 ppm
o AFP≥ 100 ng/mL
hnRNP K ≥7.160 ppm
or AFP≥ 400 ng/mL
hnRNP KL ≥7.160 ppm
and op AFP≥ 100 ng/mL
hnRNP K ≥7.160 ppm
and AFP≥ 400 ng/mL
Sensitivity (Sen) 93.33 % 93.33 % 33.33 % 33.33 %
Specificity (Spe) 44.00 % 32.00 % 96.00 % 92.00 %
False negative
rate (FNR)
0.0667 0.0667 0.6667 0.6667
False positive
rate (FPR)
0.5600 0.6800 0.0400 0.0800
Youden index 0.3733 0.2533 0.2933 0.2533
Positive predictive
value (PPV)
0.5000 0.4516 0.8333 0.7143
Negative predictive
value (NPV)
0.9167 0.8889 0.7059 0.6970
Accuracy 0.6250 0.5500 0.7250 0.7000
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ation of aberrant expression of hnRNP K in additional in-
dependent HCC tissues further reinforced the use of
hnRNP K as a potential tumor marker. Correlation ana-
lysis showed that hnRNP K was not only a potential bio-
marker for the detection of early HCC, but also the
expression level of this protein was positively corre-
lated with the increased tumor size and the presence
of microsatellites. This demonstrated that hnRNP K
overexpression may be related to active tumor growth
and intrahepatic micrometastasis.
hnRNP K has been shown to be involved in a number
of cellular functions [18,19]. It also exhibits specific
binding and transactivation within the c-myc promoter
[20,21]. In addition, p53 and hnRNP K cooperate to aug-
ment transcription of target genes. Tumors simultan-
eously expressing p53 and hnRNP K are more aggressive
[22]. In 2005, researchers identified an association be-
tween hnRNP K and the amount of HBV replication in
the liver. Overexpression of hnRNP K augmented HBV
replication, while gene silencing of endogenous hnRNP
K carried out by small interfering RNAs resulted in a
significant reduction of HBV viral load. This suggested
that hnRNP K may act in concert to support the replica-
tion activity of HBV in the host [23]. In addition, hnRNP
K protein promotes hepatocyte proliferation. Levels of
nuclear K protein were higher in proliferating compared
to resting hepatocyte [24]. It has also been demonstrated
that hnRNP share three same proline-rich sequences
with HCV core protein-binding domain. HCV core pro-
tein relieved the suppression effect of hnRNP K on the
activity of the human thymidine kinase gene promoter
[25]. These data further proved that hnRNP K may be
involved in the multistep process of hepatocarcinogen-
esis, and eventually lead to cirrhosis and HCC by sup-
porting HBV and HCV replication and cell proliferation.Our verification by immunohistochemisty demon-
strated that more intensive hnRNP K activity was found
to localize in the nucleus compared to the cytoplasm of
tumor cells, whereas faint nuclear immunostaining was
observed in cirrhotic tissues. This finding is similar to a
previous report that the hnRNP K expression level
increased and translocated from the nucleus to the cyto-
plasm in colon cancer tissue [24]. The underlying mo-
lecular mechanism of hnRNP K translocation in tumor
tissue need further elucidation. However, it is reasonable
to infer that hnRNP K plays a different role in tumor tis-
sue versus HBV-associated cirrhosis tissue. hnRNP K
may act as a shuttle to transport important factors sup-
porting cell growth and proliferation in tumor tissue. In
HBV-associated cirrhosis tissue, hnRNP K may be
involved in regulating DNA transcription to promote
HBV replication. This may cause chronic liver injury,
and eventually lead to the malignant transformation of
the hepatocytes.
hnRNP K has been found to be overexpressed in and
correlated with a poor prognosis in human prostate,
lung, pancreatic, and colorectal [26–28]. The feasibility
of using hnRNP K as a screening tool and a diagnostic
biomarker for cancer still remains undefined. In the
present study, we found that hnRNP K is overexpressed
in individuals with HCC of all sizes and that it could dis-
tinguish early HCC from late HCC. This makes it a can-
didate biomarker for HCC screening in patients with
high risk HBV infection. We compared the capability of
tissue hnRNP K with serum AFP (cutoff thresholds:
100 ng/mL) in diagnosing early HCC, and as expected,
hnRNP K showed a better performance than AFP in
detecting early HCC (sensitivity: 66.7% vs. 64.29%, speci-
ficity: 84% vs. 56%). Because a single biomarker will not
provide information regarding both tissue type and ma-
lignant transformation throughout the various stages of
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bined tissue hnRNP K intensity and serum AFP concen-
tration to form a biomarker panel. This enhanced both
the sensitivity and specificity by parallel and serial tests.
The results showed that parallel test with tissue hnRNP
K intensity and serum AFP cutoff thresholds optimized
sensitivity (93.33%), whereas serial test optimized test
specificity (96%). The combined use of hnRNP K and
serum AFP has improved utility for screening and diag-
nosing early HCC in cirrhotic tissue.
Our study describes for the first time the usefulness of
hnRNP K as a tumor biomarker for detecting early
HCC, especially the detection of early HCC from liver
cirrhosis. The 2-DE and immunohistochemistry data
showed that hnRNP K is a specific biomarker for tumor
tissue. Detecting hnRNP K expression in tissue may fa-
cilitate the accuracy of HCC diagnosis. Both the general
histodiagnosis of small nodules and the distinction of
high-grade dysplastic nodules form early HCC are ex-
tremely challenging, a positivity of hnRNP K staining in
tissue could be taken as indicator of HCC. Despite these
interesting findings, larger sample size in a randomized
study is needed to fully assess the clinical value of
hnRNP K. The potential application of noninvasive
blood testing of hnRNP K level to detect early HCC
needs to be further investigated.
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